1. VSV-G Envelope Glycoprotein Forms Complexes with Plasmid DNA and MLV Retrovirus-like Particles in Cell-free Conditions and Enhances DNA Transfection 
Tatsuya Okimoto, Theodore Friedmann, Atsushi Miyanohara 
Molecular Therapy 
Volume 4, Issue 3, Pages (September 2001)
DOI: /mthe
Copyright © 2001 American Society for Gene Therapy Terms and Conditions

2. FIG. 1
Comparison of DNA transfection mediated by CaPO4 and VSV-G. Transfections were carried out in 12-well plates using 2 μg pCMVLuc DNA per well. Luciferase activity was measured as described in the Materials and Methods. The experiments were performed in triplicate and the data represent means ± standard deviations. Hatched bars indicate CaPO4-mediated transfection and filled bars represent transfection mediated by DNA–VSV-G complexes.
Molecular Therapy 2001 4, DOI: ( /mthe )
Copyright © 2001 American Society for Gene Therapy Terms and Conditions

3. FIG. 2
Physical association between VSV-G and plasmid DNA. Samples of VSV-G, plasmid DNA, and a mixture of VSV-G and plasmid DNA with and without Polybrene were analyzed by equilibrium buoyant density sucrose gradient sedimentation. Gradient fractions were analyzed for DNA by OD260 (A), for VSV-G by western blot analysis (B), and for DNA transfection activity. Transfection was measured by addition of 50 μl of each fraction to 208F cells in the presence of Polybrene (4 μg/ml) and luciferase activity was detected 48 h after transfection (C).
Molecular Therapy 2001 4, DOI: ( /mthe )
Copyright © 2001 American Society for Gene Therapy Terms and Conditions

4. FIG. 3
Physical association of VSV-G, plasmid DNA, and MLV VLPs. Samples shown at the right were layered on 10–50% continuous sucrose gradient and centrifuged. (A) Distribution of MLV VLPs as determined by reverse transcriptase activity assay. (B) Distribution of VSV-G as detected by western blot using the anti-VSV-G antibody P5D4. (C) Distribution of DNA transfection activity measured by luciferase activity expressed in the 208F cells transfected with 50 μl of each fraction in the presence of Polybrene (4 μg/ml).
Molecular Therapy 2001 4, DOI: ( /mthe )
Copyright © 2001 American Society for Gene Therapy Terms and Conditions